Correlations between Clinical and Brain Volume Effects of Oral Valiltramiprosate in APOE4/4 Homozygotes with MCI: Pre-specified Analyses of the Phase-3 APOLLOE4 78-Week Trial in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD) (P6-12.010)

June 9, 2026Neurology

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the effects of valiltramiprosate on clinical and brain volume outcomes in APOE4 homozygotes with mild cognitive impairment.
Phase-3 trial with APOE4/4 homozygotes diagnosed with early Alzheimer's Disease.
Participants received valiltramiprosate over 78 weeks.
Pre-specified analyses of clinical and brain volume changes.
Valiltramiprosate improved clinical outcomes significantly at 78 weeks.
Significant correlations between clinical improvements and increased brain volume were observed.
Detailed statistics on event rates and effect sizes were provided.

Evaluates clinical and brain volume effects of valiltramiprosate in APOE4 homozygotes, suggesting significant outcomes.

To evaluate valiltramiprosate/ALZ-801 effects on clinical and brain volume outcomes and their correlations over 78 weeks.

No takes yet. Share an insight, caveat, or question.

Sabbagh et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share